Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Asset Writedowns and Impairment (2016 - 2024)

Historic Asset Writedowns and Impairment for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 7 years, with Q2 2024 value amounting to -$1.4 million.

  • Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment fell 24020.0% to -$1.4 million in Q2 2024 from the same period last year, while for Feb 2024 it was $47.5 million, marking a year-over-year decrease of 3839.22%. This contributed to the annual value of $1.3 million for FY2023, which is 9833.64% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Asset Writedowns and Impairment stood at -$1.4 million for Q2 2024, which was down 24020.0% from $1.4 million recorded in Q1 2024.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment ranged from a high of $46.1 million in Q2 2022 and a low of -$1.4 million during Q2 2024
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $67000.0 (2020), whereas its average is $7.0 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment skyrocketed by 4765671.64% in 2021, and later plummeted by 24020.0% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment stood at $67000.0 in 2020, then skyrocketed by 47656.72% to $32.0 million in 2021, then skyrocketed by 44.04% to $46.1 million in 2022, then tumbled by 97.83% to $1.0 million in 2023, then plummeted by 240.2% to -$1.4 million in 2024.
  • Its last three reported values are -$1.4 million in Q2 2024, $1.4 million for Q1 2024, and $1.0 million during Q2 2023.